Publication
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- drugPonatinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22238366
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Amplification1 | ||||||||
| Ponatinib | Malignant Gastric Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8062In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and containing FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC | civic |
| FGFR3 Amplification1 | ||||||||
| Ponatinib | Malignant Gastric Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | rejected | EID8061In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and containing FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC | civic |
| FGFR3 S249C1 | ||||||||
| Ponatinib | Transitional Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8060In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and containing FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC | civic |
| FGFR1 Amplification1 | ||||||||
| Ponatinib | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1767In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 valu… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC | civic |